Improving Clinical Trial Capacity in Asia: Malaysia

Dr Akhmal Yusof
CEO, Clinical Research Malaysia

Content

- Introduction
- The Landscape
- Opportunity
- Charting the Future

Malaysia at a Glance



Consists of 13 states and three federal territories

32.69 million population

in third quarter 20201

0 - 14 years : **23**%

15 – 64 years : **70%** 65+ years : **7%**

Comprises of Multiethnicities - Malay (69.6%), Chinese (22.6%), Indian (6.8%), others $(1\%)^1$

1/3 of World Population Genomics in Malaysia



Establishment

Corporatized company and owned by Ministry of Health One-stop centre & Site Management Organisation (SMO)



Self-Sustainable



ISO 9001:2015 (QMS) accreditation

Quality Management System



ISO37001:2016 (ABMS) accreditation

Anti-Bribery Management System



10-Year Milestone



PLANNING STAGE

Site/Country Selection Process



One Stop Centre

for both Sponsors and CROs



Fast and Accurate Feasibility Database of Malaysia

since 2012, updated every 6 months-information on site capabilities, investigators across all therapeutic areas



111

Budget Negotiations and Enquiries



Legal Enquiries CTAs, NDA/CDAs

Regulatory and IRB Submissions Enquiries



Malaysian Sites & Investigators

175

Public Hospitals / Health Clinics

15

MOHE Hospitals

69

Private Hospitals

1700

Investigators Multi Therapeutic

CROs

Sponsors

(Pharmaceutical, Biotechnology,

and Medical Device Companies)

(Contract Research Organization)

STUDIES AWARDED TO MALAYSIA / APPROVED STUDIES IN MALAYSIA

Ensure Sites & Investigators focus on the delivery of trials by

Supplying qualified and high quality study coordinator



Reviewing of all **Clinical Trials** Agreement



Handling investigators trial budget in a transparent manner



Tackling issues at the site level including recruitment



Sponsors & CROs









Your Global Solutions in One Nation

CRM's Guiding Principles



HUMANITY

Address unmet medical needs, access to innovative treatments and transform health outcomes for patients through clinical trials

STABILITY

Excellent & consistent performance to deliver speed, reliability & quality





SUSTAINABILITY

Create business sustainability through core values, code of conduct & operational excellence

The Promise of Clinical Trials: Transforming Tomorrow's Health


SCRI Clinical Trials Symposium 2024

30 - 31 Jul 2024 • Raffles City Convention Centre



Landscape

Sponsored Clinical Research in Malaysia (n=2305)



RECRUITMENT ACHIEVEMENTS IN GLOBAL SPONSORED RESEARCH 2024

Global Top Recruiter

Sultanah Aminah Hospital

Dr Muhammad Firdaus Ulcerative Colitis

Global 1st Recruiter

Sarawak General Hospital

Dr Voon Pei Jye Carcinoma, Non-Small-Cell Lung Cancer

Queen Elizabeth II Hospital

Dr Liew Houng Bang Acute Myocardial Infarction (AMI)

APAC 1st Recruiter

Sultan Idris Shah Hospital

Dr Fairol Huda Ibrahim Active Lupus Nephritis

Pulau Pinang Hospital

Dr Choong Swee Hsia Melanoma

Sultanah Aminah Hospital

Dr Boo Yang Liang Chronic Lymphocytic Leukemia

MALAYSIA 1st Recruiter

Pantai Hospital Kuala Lumpur

Dr Mastura Md Yusof
• Triple Negative Breast
Cancer

- Breast Cancer
- Endometrial Cancer
- Metastatic Breast Cancer

University Malaya Medical Center

Assoc. Prof. Dr Wan Zamaniah Solid Tumors

Dr Wong Chee Kuan Chronic Obstructive Pulmonary Disease

Dr Aishah Binti Ibrahim Chronic Obstructive Pulmonary Disease

Sultanah Bahiyah Hospital

Dr Zalwani Zainuddin Functional Dyspepsia

Dr Abd Syukur Abdullah Heart Failure

Sultanah Fatimah Specialist Hospital

Dr Evelyn Yap Wen Yee Chronic Inducible Urticaria

Dr Zaid Bin Azhari Uncontrolled Hypertension

Queen Elizabeth II Hospital

Dr Liew Houng Bang Atrial Fibrillation

Miri Hospital

Dato' Dr Fam Tem Lom
• Cardiovascular Disease
• Dengue

Sarawak General Hospital

Dr Chua Hock Hin HIV-1 Infection


Seri Manjung Hospital


Dr Lee Li Yuan Gout Patients with Hyperuricemia

Pulau Pinang Hospital

Dr Soo Hoo Hwoei Fen Breast Cancer

Clinical Trial Distribution





ATLAS Study Milestone

Top 5 recruiting ATLAS sites (as of Dec. 12)

	MKA	CHOICE	HARMONY	ATRAIN	Total
	(Nov. 30)	(Sep. 29)	(Dec. 12)	(Dec. 12)	iotai
National Cancer Center Hospital (JP)	-	-	24	99	123
Hospital Pulau Pinang (MY)	103	5	-	-	108
Sarawak General Hospital (MY)	63	2	-	27	92
Institut Kanser Negara (MY)	63	5	-	19	87
National Taiwan University Hospital(TW)	22	0	-	52	74
K Hospital (VN)	30	-	-	41	71
St. Luke's Medical Center (PH)	35	0	3	20	58
University Malaya Medical Center (MY)	36	5	-	16	57
Hospital Kuala Lumpur (MY)	41	0	-	12	53
Hospital Sultan Ismail (MY)	49	1	-	-	50
Siriraj Hospital (TH)	19	12	-	9	40
National Cancer Center Korea (KR)	37	-	-	-	37
Srinagarind Hospital (TH)	22	11	-	-	33
Ho Chi Minh City Oncology Hospital (VN)	-	-	-	31	31
Taipei Veterans General Hospotal (TW)	19	9	-	-	28
National Cancer Centre Singapore (SG)	-	-	-	17	17
National University Hospital (SG)	-	-	-	16	16
Ramathibodi Hospital (TH)	5	1	-	9	15
Pusan National University Hospital(KR)	10	-	-	-	10
Prince of Sonkla University Hospital (TH)	6	2	-	0	8
Vajira Hospital (TH)	-	-	-	7	7
King Chulalongkorn Memorial Hospital (TH)	-	-	-	5	5
Phramongkutklao Hospital (TH)	-	-	-	4	4
Maharaj Nakorn Chiang Mai Hospital(TH)	2	1	-	1	4
Severance Hospital Yonsei University Health System (KR)	-	-	-	1	1
	562	54	27	386	1029

Updated during 5th ATLAS Semiannual Meeting 22 Dec 2023

ATLAS BOARD MEMBER & EORTC CONVENTION 2024


Opportunity

SPEED - Improved Start-up

MREC Review



CTA Review



Reduced from **60 days to 14 days**



The timeline to review the CDA:

24 working hours




The timeline to review the CTA:

14 calendar days



ium for Asia Regulatory Coordination lishment of PMDA Asia Office~ **Develop Clinical Research Professionals**

- CRM Study Coordinators





P1RP

P1RP 2.0

Updates: FIH Study in SGH -1st Patient dosed in June 2023

Structured FIH **Ecosystem** Phase 1 Guidelines

Scientific Review Panel

NPRA Accreditation Program 2 Regulatory officers - UK

2 SCs - NUH Singapore

2 SCs & 2 Pls - NCC Japan

Capability Development

FIH/ Early Phase **Expertise**



3 Regulatory Officers

1 Investigator

NPRA's acceptance of FIH biologics

International events & global partnerships

IKN - Support for lab accreditation

FIH Accredited | Site

2 Sites

Site Development

Improve

Access

1H 2024 Activities & Outcome

Activities	Outcome		
National Taiwan University Hospital	CRM Study Coordinator Observer ship		
DIA USA Annual Meeting	CRM & NPRA participate as delegate		
MoU with CUHK	New opportunity for CRM SC training in Phase 1		
18th ASEAN SOMHD & AHMM	ASEAN Prosperity through ISCT		

Charting the future



2033

VISION

To be the preferred hub for clinical research in Asia

MISSION



Global Trusted Research Management Organisation



Clinical Research
Professions Development



Digitalise Processes

Centre of Excellence (CoE)

Program: Study Coordinator Foundation 12-week program

ACCOMPLISHED

1st Batch Intake graduated on 14 June (8 trainees)

- 3 already employed as CRM SCs

ONGOING

2nd Batch: 11 Jul – 27 Sep 2024 (10 trainees)







CRM Trial Connect 2025

1000 attendees

14 Sponsor Exhibitors

14 Countries

142 Organisations













National Conference for Clinical Research (NCCR)

CRM Trial Connect 2025

7-9 May 2025

ATLAS, EORTC and NCC Japan

The largest clinical research conference in SEA

Excellent ratings on program, quality speakers and topics

Thank You For Your Attention

